☰

Valentin K. Gribkoff - Publications

Affiliations: 
Knopp Neurosciences Inc., Pittsburgh, PA, United States 

97 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Alavian KN, Dworetzky SI, Bonanni L, Zhang P, Sacchetti S, Li H, Signore AP, Smith PJ, Gribkoff VK, Jonas EA. The mitochondrial complex V-associated large-conductance inner membrane current is regulated by cyclosporine and dexpramipexole. Molecular Pharmacology. 87: 1-8. PMID 25332381 DOI: 10.1124/mol.114.095661  1
2013 Wu YJ, Conway CM, Sun LQ, Machet F, Chen J, Chen P, He H, Bourin C, Calandra V, Polino JL, Davis CD, Heman K, Gribkoff VK, Boissard CG, Knox RJ, et al. Discovery of (S,E)-3-(2-fluorophenyl)-N-(1-(3-(pyridin-3-yloxy)phenyl)ethyl)-acrylamide as a potent and efficacious KCNQ2 (Kv7.2) opener for the treatment of neuropathic pain. Bioorganic & Medicinal Chemistry Letters. 23: 6188-91. PMID 24070783 DOI: 10.1016/j.bmcl.2013.08.092  1
2012 Alavian KN, Dworetzky SI, Bonanni L, Zhang P, Sacchetti S, Mariggio MA, Onofrj M, Thomas A, Li H, Mangold JE, Signore AP, Demarco U, Demady DR, Nabili P, Lazrove E, ... ... Gribkoff VK, et al. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Research. 1446: 1-11. PMID 22364637 DOI: 10.1016/j.brainres.2012.01.046  1
2011 Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, Moore DH, Schoenfeld D, Mather JL, Archibald D, Sullivan M, Amburgey C, Moritz J, Gribkoff VK. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nature Medicine. 17: 1652-6. PMID 22101764 DOI: 10.1038/nm.2579  1
2011 Bozik ME, Mather JL, Kramer WG, Gribkoff VK, Ingersoll EW. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. Journal of Clinical Pharmacology. 51: 1177-85. PMID 20959524 DOI: 10.1177/0091270010379412  1
2008 Gribkoff VK, Bozik ME. KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. Cns Neuroscience & Therapeutics. 14: 215-26. PMID 18801114 DOI: 10.1111/j.1755-5949.2008.00048.x  1
2008 Gribkoff VK. The therapeutic potential of neuronal K V 7 (KCNQ) channel modulators: an update. Expert Opinion On Therapeutic Targets. 12: 565-81. PMID 18410240 DOI: 10.1517/14728222.12.5.565  1
2008 Gribkoff VK, Kaczmarek LK. Regulation of Neuronal Excitability by the Sodium-Activated Potassium Channels Slick (SLO2.1) and Slack (SLO2.2) Structure, Function, and Modulation of Neuronal Voltagegated Ion Channels. 193-215. DOI: 10.1002/9780470429907.ch7  1
2008 Dworetzky SI, Gribkoff VK. Neuronal Kv7 Potassium Channels as Emerging Targets for the Treatment of Pain Structure, Function, and Modulation of Neuronal Voltagegated Ion Channels. 393-421. DOI: 10.1002/9780470429907.ch15  1
2008 Gribkoff VK, Kaczmarek LK. Preface Structure, Function, and Modulation of Neuronal Voltagegated Ion Channels. ix-x. DOI: 10.1002/9780470429907  1
2007 Vrudhula VM, Dasgupta B, Qian-Cutrone J, Kozlowski ES, Boissard CG, Dworetzky SI, Wu D, Gao Q, Kimura R, Gribkoff VK, Starrett JE. Atropisomeric 3-(beta-hydroxyethyl)-4-arylquinolin-2-ones as Maxi-K potassium channel openers. Journal of Medicinal Chemistry. 50: 1050-7. PMID 17274609 DOI: 10.1021/jm061093j  1
2007 Romine JL, Martin SW, Meanwell NA, Gribkoff VK, Boissard CG, Dworetzky SI, Natale J, Moon S, Ortiz A, Yeleswaram S, Pajor L, Gao Q, Starrett JE. 3-[(5-Chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl ]-1,3,4-oxadiazol-2(3H)-one, BMS-191011: opener of large-conductance Ca(2+)-activated potassium (maxi-K) channels, identification, solubility, and SAR. Journal of Medicinal Chemistry. 50: 528-42. PMID 17266205 DOI: 10.1021/jm061006n  1
2006 Gribkoff VK. The role of voltage-gated calcium channels in pain and nociception. Seminars in Cell & Developmental Biology. 17: 555-64. PMID 17141538 DOI: 10.1016/j.semcdb.2006.09.002  1
2006 Lindner MD, Hogan JB, Hodges DB, Orie AF, Chen P, Corsa JA, Leet JE, Gillman KW, Rose GM, Jones KM, Gribkoff VK. Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping. Psychopharmacology. 188: 629-40. PMID 17004085 DOI: 10.1007/s00213-006-0556-3  1
2006 Yang B, Gribkoff VK, Pan J, Damagnez V, Dworetzky SI, Boissard CG, Bhattacharjee A, Yan Y, Sigworth FJ, Kaczmarek LK. Pharmacological activation and inhibition of Slack (Slo2.2) channels. Neuropharmacology. 51: 896-906. PMID 16876206 DOI: 10.1016/j.neuropharm.2006.06.003  1
2006 Lindner MD, Hogan JB, Krause RG, Machet F, Bourin C, Hodges DB, Corsa JA, Barten DM, Toyn JH, Stock DA, Rose GM, Gribkoff VK. Soluble Abeta and cognitive function in aged F-344 rats and Tg2576 mice. Behavioural Brain Research. 173: 62-75. PMID 16828889 DOI: 10.1016/j.bbr.2006.06.003  1
2006 Gribkoff VK. Voltage-gated sodium channels in spinal ganglia: Tempting targets for new pain medications Drug Discovery Today: Therapeutic Strategies. 3: 585-591. DOI: 10.1016/j.ddstr.2006.11.004  1
2005 Vrudhula VM, Dasgupta B, Boissard CG, Gribkoff VK, Santone KS, Dalterio RA, Lodge NJ, Starrett JE. Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes. Bioorganic & Medicinal Chemistry Letters. 15: 4286-90. PMID 16061379 DOI: 10.1016/j.bmcl.2005.06.056  1
2005 Winquist RJ, Pan JQ, Gribkoff VK. Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain. Biochemical Pharmacology. 70: 489-99. PMID 15950195 DOI: 10.1016/j.bcp.2005.04.035  1
2005 Gribkoff VK, Winquist RJ. Voltage-gated cation channel modulators for the treatment of stroke. Expert Opinion On Investigational Drugs. 14: 579-92. PMID 15926865 DOI: 10.1517/13543784.14.5.579  1
2005 Gribkoff VK, Winquist RJ. Modulators of peripheral voltage-gated sodium channels for the treatment of neuropathic pain Expert Opinion On Therapeutic Patents. 15: 1751-1762. DOI: 10.1517/13543776.15.12.1751  1
2004 Boy KM, Guernon JM, Sit SY, Xie K, Hewawasam P, Boissard CG, Dworetzky SI, Natale J, Gribkoff VK, Lodge N, Starrett JE. 3-Thio-quinolinone maxi-K openers for the treatment of erectile dysfunction. Bioorganic & Medicinal Chemistry Letters. 14: 5089-93. PMID 15380205 DOI: 10.1016/j.bmcl.2004.07.080  1
2004 Wu YJ, Sun LQ, He H, Chen J, Starrett JE, Dextraze P, Daris JP, Boissard CG, Pieschl RL, Gribkoff VK, Natale J, Knox RJ, Harden DG, Thompson MW, Fitzpatrick W, et al. Synthesis and KCNQ2 opener activity of N-(1-benzo[1,3]dioxol-5-yl-ethyl, N-[1-(2,3-dihydro-benzofuran-5-yl)-ethyl, and N-[1-(2,3-dihydro-1H-indol-5-yl)-ethyl acrylamides. Bioorganic & Medicinal Chemistry Letters. 14: 4533-7. PMID 15357987 DOI: 10.1016/j.bmcl.2004.06.035  1
2004 Hewawasam P, Fan W, Cook DA, Newberry KS, Boissard CG, Gribkoff VK, Starrett J, Lodge NJ. 4-Aryl-3-(mercapto)quinolin-2-ones: novel maxi-K channel opening relaxants of corporal smooth muscle. Bioorganic & Medicinal Chemistry Letters. 14: 4479-82. PMID 15357975 DOI: 10.1016/j.bmcl.2004.06.051  1
2004 Wu YJ, He H, Sun LQ, L'Heureux A, Chen J, Dextraze P, Starrett JE, Boissard CG, Gribkoff VK, Natale J, Dworetzky SI. Synthesis and structure-activity relationship of acrylamides as KCNQ2 potassium channel openers. Journal of Medicinal Chemistry. 47: 2887-96. PMID 15139767 DOI: 10.1021/jm0305826  1
2004 Wu YJ, Boissard CG, Chen J, Fitzpatrick W, Gao Q, Gribkoff VK, Harden DG, He H, Knox RJ, Natale J, Pieschl RL, Starrett JE, Sun LQ, Thompson M, Weaver D, et al. (S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons. Bioorganic & Medicinal Chemistry Letters. 14: 1991-5. PMID 15050644 DOI: 10.1016/j.bmcl.2004.01.069  1
2004 Hewawasam P, Chen N, Ding M, Natale JT, Boissard CG, Yeola S, Gribkoff VK, Starrett J, Dworetzky SI. The synthesis and structure-activity relationships of 3-amino-4-benzylquinolin-2-ones; discovery of novel KCNQ2 channel openers. Bioorganic & Medicinal Chemistry Letters. 14: 1615-8. PMID 15026035 DOI: 10.1016/j.bmcl.2004.01.073  1
2003 Lindner MD, Gribkoff VK, Donlan NA, Jones TA. Long-lasting functional disabilities in middle-aged rats with small cerebral infarcts. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 10913-22. PMID 14645487  1
2003 Gribkoff VK. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opinion On Therapeutic Targets. 7: 737-48. PMID 14640909 DOI: 10.1517/14728222.7.6.737  1
2003 Lindner MD, Hodges DB, Hogan JB, Orie AF, Corsa JA, Barten DM, Polson C, Robertson BJ, Guss VL, Gillman KW, Starrett JE, Gribkoff VK. An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning. The Journal of Pharmacology and Experimental Therapeutics. 307: 682-91. PMID 12975483 DOI: 10.1124/jpet.103.056002  1
2003 Wu YJ, Boissard CG, Greco C, Gribkoff VK, Harden DG, He H, L'Heureux A, Kang SH, Kinney GG, Knox RJ, Natale J, Newton AE, Lehtinen-Oboma S, Sinz MW, Sivarao DV, et al. (S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine. Journal of Medicinal Chemistry. 46: 3197-200. PMID 12852750 DOI: 10.1021/jm034073f  1
2003 Hewawasam P, Fan W, Ding M, Flint K, Cook D, Goggins GD, Myers RA, Gribkoff VK, Boissard CG, Dworetzky SI, Starrett JE, Lodge NJ. 4-Aryl-3-(hydroxyalkyl)quinolin-2-ones: novel maxi-K channel opening relaxants of corporal smooth muscle targeted for erectile dysfunction. Journal of Medicinal Chemistry. 46: 2819-22. PMID 12825925 DOI: 10.1021/jm030005h  1
2003 Gribkoff VK, Pieschl RL, Dudek FE. GABA receptor-mediated inhibition of neuronal activity in rat SCN in vitro: pharmacology and influence of circadian phase. Journal of Neurophysiology. 90: 1438-48. PMID 12750413 DOI: 10.1152/jn.01082.2002  1
2003 Hewawasam P, Ding M, Chen N, King D, Knipe J, Pajor L, Ortiz A, Gribkoff VK, Starrett J. Synthesis of water-soluble prodrugs of BMS-191011: a maxi-K channel opener targeted for post-stroke neuroprotection. Bioorganic & Medicinal Chemistry Letters. 13: 1695-8. PMID 12729644 DOI: 10.1016/S0960-894X(03)00296-8  1
2003 Li Y, Johnson G, Romine JL, Meanwell NA, Martin SW, Dworetzky SI, Boissard CG, Gribkoff VK, Starrett JE. Novel openers of Ca2+-dependent large-conductance potassium channels: symmetrical pharmacophore and electrophysiological evaluation of bisphenols. Bioorganic & Medicinal Chemistry Letters. 13: 1437-9. PMID 12668007 DOI: 10.1016/S0960-894X(03)00156-2  1
2003 Jin X, von Gall C, Pieschl RL, Gribkoff VK, Stehle JH, Reppert SM, Weaver DR. Targeted disruption of the mouse Mel(1b) melatonin receptor. Molecular and Cellular Biology. 23: 1054-60. PMID 12529409 DOI: 10.1128/MCB.23.3.1054-1060.2003  1
2003 Dischino DD, Gribkoff VK, Hewawasam P, Luke GM, Rinehart JK, Spears TL, Starrett JE. Synthesis of 3H and 14C labeled (S)-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6- (trifluoromethyl)-2H-indol-2-one, Maxipostâ„¢. An agent for post-stroke neuroprotection Journal of Labelled Compounds and Radiopharmaceuticals. 46: 139-149. DOI: 10.1002/jlcr.652  1
2002 Romine JL, Martin SW, Gribkoff VK, Boissard CG, Dworetzky SI, Natale J, Li Y, Gao Q, Meanwell NA, Starrett JE. 4,5-diphenyltriazol-3-ones: openers of large-conductance Ca(2+)-activated potassium (maxi-K) channels. Journal of Medicinal Chemistry. 45: 2942-52. PMID 12086481 DOI: 10.1021/jm010569q  1
2002 Hewawasam P, Fan W, Knipe J, Moon SL, Boissard CG, Gribkoff VK, Starrett JE. The synthesis and structure-activity relationships of 4-aryl-3-aminoquinolin-2-ones: a new class of calcium-dependent, large conductance, potassium (maxi-K) channel openers targeted for post-stroke neuroprotection. Bioorganic & Medicinal Chemistry Letters. 12: 1779-83. PMID 12067560 DOI: 10.1016/S0960-894X(02)00240-8  1
2002 Hewawasam P, Erway M, Thalody G, Weiner H, Boissard CG, Gribkoff VK, Meanwell NA, Lodge N, Starrett JE. The synthesis and structure-activity relationships of 1,3-diaryl 1,2,4-(4H)-triazol-5-ones: a new class of calcium-dependent, large conductance, potassium (maxi-K) channel opener targeted for urge urinary incontinence. Bioorganic & Medicinal Chemistry Letters. 12: 1117-20. PMID 11909730 DOI: 10.1016/S0960-894X(02)00099-9  1
2002 Hewawasam P, Gribkoff VK, Pendri Y, Dworetzky SI, Meanwell NA, Martinez E, Boissard CG, Post-Munson DJ, Trojnacki JT, Yeleswaram K, Pajor LM, Knipe J, Gao Q, Perrone R, Starrett JE. The synthesis and characterization of BMS-204352 (MaxiPost) and related 3-fluorooxindoles as openers of maxi-K potassium channels. Bioorganic & Medicinal Chemistry Letters. 12: 1023-6. PMID 11909708 DOI: 10.1016/S0960-894X(02)00101-4  1
2002 Hewawasam P, Erway M, Moon SL, Knipe J, Weiner H, Boissard CG, Post-Munson DJ, Gao Q, Huang S, Gribkoff VK, Meanwell NA. Synthesis and structure-activity relationships of 3-aryloxindoles: a new class of calcium-dependent, large conductance potassium (maxi-K) channel openers with neuroprotective properties. Journal of Medicinal Chemistry. 45: 1487-99. PMID 11906290 DOI: 10.1021/jm0101850  1
2002 Kiesewetter DO, Jagoda EM, Starrett JE, Gribkoff VK, Hewawasam P, Srinivas N, Salazar D, Eckelman WC. Radiochemical synthesis and biodistribution of a novel maxi-K potassium channel opener. Nuclear Medicine and Biology. 29: 55-9. PMID 11786276 DOI: 10.1016/S0969-8051(01)00281-5  1
2002 Gribkoff VK, Starrett JE. Chapter 24. Advances in technologies for the discovery and characterization of ion channel modulators: Focus on potassium channels Annual Reports in Medicinal Chemistry. 37: 237-246.  1
2001 Gribkoff VK, Starrett JE, Dworetzky SI. Maxi-K potassium channels: form, function, and modulation of a class of endogenous regulators of intracellular calcium. The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry. 7: 166-77. PMID 11496927  1
2001 Cheney JA, Weisser JD, Bareyre FM, Laurer HL, Saatman KE, Raghupathi R, Gribkoff V, Starrett JE, McIntosh TK. The maxi-K channel opener BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 21: 396-403. PMID 11323525 DOI: 10.1097/00004647-200104000-00008  1
2001 Gribkoff VK, Starrett JE, Dworetzky SI, Hewawasam P, Boissard CG, Cook DA, Frantz SW, Heman K, Hibbard JR, Huston K, Johnson G, Krishnan BS, Kinney GG, Lombardo LA, Meanwell NA, et al. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nature Medicine. 7: 471-7. PMID 11283675 DOI: 10.1038/86546  1
2000 Kinney GG, Taber MT, Gribkoff VK. The augmentation hypothesis for improvement of antidepressant therapy: is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency? Molecular Neurobiology. 21: 137-52. PMID 11379796 DOI: 10.1385/MN:21:3:137  1
2000 Taber MT, Kinney GG, Pieschl RL, Yocca FD, Gribkoff VK. Differential effects of coadministration of fluoxetine and WAY-100635 on serotonergic neurotransmission in vivo: sensitivity to sequence of injections. Synapse (New York, N.Y.). 38: 17-26. PMID 10941137 DOI: 10.1002/1098-2396(200010)38:1<17::AID-SYN3>3.0.CO;2-5  1
1999 Gribkoff VK, Starrett JE. An assessment of the present and future roles of non-ligand gated ion channel modulators as CNS therapeutics. Expert Opinion On Pharmacotherapy. 1: 61-70. PMID 11249565 DOI: 10.1517/14656566.1.1.61  1
1999 Kinney GG, Patino P, Mermet-Bouvier Y, Starrett JE, Gribkoff VK. Cognition-enhancing drugs increase stimulated hippocampal theta rhythm amplitude in the urethane-anesthetized rat. The Journal of Pharmacology and Experimental Therapeutics. 291: 99-106. PMID 10490892  1
1999 Gribkoff VK, Pieschl RL, Wisialowski TA, Park WK, Strecker GJ, de Jeu MT, Pennartz CM, Dudek FE. A reexamination of the role of GABA in the mammalian suprachiasmatic nucleus. Journal of Biological Rhythms. 14: 126-30. PMID 10194649  1
1998 Joiner WJ, Tang MD, Wang LY, Dworetzky SI, Boissard CG, Gan L, Gribkoff VK, Kaczmarek LK. Formation of intermediate-conductance calcium-activated potassium channels by interaction of Slack and Slo subunits. Nature Neuroscience. 1: 462-9. PMID 10196543 DOI: 10.1038/2176  1
1998 Gribkoff VK, Pieschl RL, Wisialowski TA, van den Pol AN, Yocca FD. Phase shifting of circadian rhythms and depression of neuronal activity in the rat suprachiasmatic nucleus by neuropeptide Y: mediation by different receptor subtypes. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 3014-22. PMID 9526018  1
1997 Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, Reppert SM. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 19: 91-102. PMID 9247266 DOI: 10.1016/S0896-6273(00)80350-5  1
1997 Gribkoff VK, Starrett JE, Dworetzky SI. The pharmacology and molecular biology of large-conductance calcium-activated (BK) potassium channels. Advances in Pharmacology (San Diego, Calif.). 37: 319-48. PMID 8891106  1
1997 Hewawasam P, Meanwell NA, Gribkoff VK, Dworetzky SI, Boissard CG. Discovery of a novel class of BK channel openers: Enantiospecific synthesis and BK channel opening activity of 3-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-3- hydroxy-6-(trifluoromethyl)-2H-indol-2-one Bioorganic and Medicinal Chemistry Letters. 7: 1255-1260. DOI: 10.1016/S0960-894X(97)00202-3  1
1997 Li Y, Starrett JE, Meanwell NA, Johnson G, Harte WE, Dworetzky SI, Boissard CG, Gribkoff VK. The discovery of novel openers of Ca2+-dependent large-conductance potassium channels: Pharmacophore search and physiological evaluation of flavonoids Bioorganic and Medicinal Chemistry Letters. 7: 759-762. DOI: 10.1016/S0960-894X(97)00076-0  1
1996 Kozlowski ES, Johnson G, Dischino DD, Dworetzky SI, Boissard CG, Gribkoff VK. Synthesis and biological evaluation of an iodinated iberiotoxin analogue, [mono-iodo-Tyr5, Phe36]-iberiotoxin. International Journal of Peptide and Protein Research. 48: 194-9. PMID 8872538  0.68
1996 Zhong J, Gribkoff VK, Molinoff PB. Use of subunit-specific antisense oligodeoxynucleotides to define developmental changes in the properties of N-methyl-D-aspartate receptors. Molecular Pharmacology. 50: 631-8. PMID 8794904  1
1996 Dworetzky SI, Boissard CG, Lum-Ragan JT, McKay MC, Post-Munson DJ, Trojnacki JT, Chang CP, Gribkoff VK. Phenotypic alteration of a human BK (hSlo) channel by hSlobeta subunit coexpression: changes in blocker sensitivity, activation/relaxation and inactivation kinetics, and protein kinase A modulation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 16: 4543-50. PMID 8764643  1
1996 Gribkoff VK, Lum-Ragan JT, Boissard CG, Post-Munson DJ, Meanwell NA, Starrett JE, Kozlowski ES, Romine JL, Trojnacki JT, Mckay MC, Zhong J, Dworetzky SI. Effects of channel modulators on cloned large-conductance calcium-activated potassium channels. Molecular Pharmacology. 50: 206-17. PMID 8700114  1
1996 Gribkoff VK, Starrett JE, Dworetzky SI. The Pharmacology and Molecular Biology of Large-Conductance Calcium = Activated (BK) Potassium Channels Advances in Pharmacology. 37: 319-348. DOI: 10.1016/S1054-3589(08)60954-0  1
1996 Meanwell NA, Sit SY, Gao J, Boissard CG, Lum-Ragan J, Dworetzky SI, Gribkoff VK. N-Benzylated benzimidazol-2-one derivatives: Activators of large-conductance Ca2+-dependent K+ channels Bioorganic and Medicinal Chemistry Letters. 6: 1641-1646. DOI: 10.1016/0960-894X(96)00296-X  1
1996 Starrett JE, Dworetzky SI, Gribkoff VK. Modulators of large-conductance calcium-activated potassium (BK) channels as potential therapeutic targets Current Pharmaceutical Design. 2: 413-428.  1
1995 Gribkoff VK, Hammang JP, Baetge EE. Reduced electrical excitability of PC12 cells deficient in GAP-43: comparison with GAP-43-positive cells. Brain Research. Molecular Brain Research. 30: 29-36. PMID 7609641 DOI: 10.1016/0169-328X(94)00267-I  1
1995 Champigny G, Imler JL, Puchelle E, Dalemans W, Gribkoff V, Hinnrasky J, Dott K, Barbry P, Pavirani A, Lazdunski M. A change in gating mode leading to increased intrinsic CI- channel activity compensates for defective processing in a cystic fibrosis mutant corresponding to a mild form of the disease Embo Journal. 14: 2417-2423. PMID 7540133  1
1994 McKay MC, Dworetzky SI, Meanwell NA, Olesen SP, Reinhart PH, Levitan IB, Adelman JP, Gribkoff VK. Opening of large-conductance calcium-activated potassium channels by the substituted benzimidazolone NS004. Journal of Neurophysiology. 71: 1873-82. PMID 8064354  1
1994 Dworetzky SI, Trojnacki JT, Gribkoff VK. Cloning and expression of a human large-conductance calcium-activated potassium channel. Brain Research. Molecular Brain Research. 27: 189-93. PMID 7877450 DOI: 10.1016/0169-328X(94)90203-8  1
1994 Post-Munson DJ, Lum-Ragan JT, Mahle CD, Gribkoff VK. Reduced bicuculline response and GABAA agonist binding in aged rat hippocampus. Neurobiology of Aging. 15: 629-33. PMID 7824055 DOI: 10.1016/0197-4580(94)00057-3  1
1994 Gribkoff VK, Champigny G, Barbry P, Dworetzky SI, Meanwell NA, Lazdunski M. The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel. The Journal of Biological Chemistry. 269: 10983-6. PMID 7512555  1
1993 Boissard CG, Gribkoff VK. The effects of the adenosine reuptake inhibitor soluflazine on synaptic potentials and population hypoxic depolarizations in area CA1 of rat hippocampus in vitro. Neuropharmacology. 32: 149-55. PMID 8383814 DOI: 10.1016/0028-3908(93)90095-K  1
1993 Lum-Ragan JT, Gribkoff VK. The sensitivity of hippocampal long-term potentiation to nitric oxide synthase inhibitors is dependent upon the pattern of conditioning stimulation. Neuroscience. 57: 973-83. PMID 7508586 DOI: 10.1016/0306-4522(93)90042-E  1
1993 Epperson JR, Hewawasam P, Meanwell NA, Boissard CG, Gribkoff VK, Post-Munson D. Synthesis and excitatory amino acid pharmacology of some novel quinoxalinediones Bioorganic and Medicinal Chemistry Letters. 3: 2801-2804. DOI: 10.1016/S0960-894X(01)80768-X  1
1992 Boissard CG, Lindner MD, Gribkoff VK. Hypoxia produces cell death in the rat hippocampus in the presence of an A1 adenosine receptor antagonist: an anatomical and behavioral study. Neuroscience. 48: 807-12. PMID 1630626 DOI: 10.1016/0306-4522(92)90268-7  1
1992 Lindner MD, Gribkoff VK. Effects of oral BMY 21502 on Morris water task performance in 16-18 month old F-344 rats. Psychopharmacology. 107: 485-8. PMID 1603891 DOI: 10.1007/BF02245260  1
1992 Gribkoff VK, Bauman LA. Endogenous adenosine contributes to hypoxic synaptic depression in hippocampus from young and aged rats. Journal of Neurophysiology. 68: 620-8. PMID 1527579  1
1992 Bauman LA, Mahle CD, Boissard CG, Gribkoff VK. Age-dependence of effects of A1 adenosine receptor antagonism in rat hippocampal slices. Journal of Neurophysiology. 68: 629-38. PMID 1388201  1
1992 Gribkoff VK, Lum-Ragan JT. Evidence for nitric oxide synthase inhibitor-sensitive and insensitive hippocampal synaptic potentiation. Journal of Neurophysiology. 68: 639-42. PMID 1382122  1
1992 Baetge EE, Hammang JP, Gribkoff VK, Meiri KF. The role of GAP-43 in the molecular regulation of axon outgrowth and electrical excitability. Perspectives On Developmental Neurobiology. 1: 21-8. PMID 1345681  1
1991 Lindner MD, Gribkoff VK. Relationship between performance in the Morris water task, visual acuity, and thermoregulatory function in aged F-344 rats. Behavioural Brain Research. 45: 45-55. PMID 1764204 DOI: 10.1016/S0166-4328(05)80179-2  1
1991 Gribkoff VK. Electrophysiological evidence for N-methyl-D-aspartate excitatory amino acid receptors in the rat supraoptic nucleus in vitro. Neuroscience Letters. 131: 260-2. PMID 1684841 DOI: 10.1016/0304-3940(91)90628-7  1
1990 Gribkoff VK, Bauman LA, VanderMaelen CP. The adenosine antagonist 8-cyclopentyltheophylline reduces the depression of hippocampal neuronal responses during hypoxia. Brain Research. 512: 353-7. PMID 2354368 DOI: 10.1016/0006-8993(90)90648-U  1
1990 Gribkoff VK, Dudek FE. Effects of excitatory amino acid antagonists on synaptic responses of supraoptic neurons in slices of rat hypothalamus. Journal of Neurophysiology. 63: 60-71. PMID 2299386  1
1990 Gribkoff VK, Bauman LA, VanderMaelen CP. A 1-heteroaryl-4-piperidinyl-methyl pyrrolidinone, BMY 21502, delays the decay of hippocampal synaptic potentiation in vitro. Neuropharmacology. 29: 1001-9. PMID 2087253 DOI: 10.1016/0028-3908(90)90105-Z  1
1988 Gribkoff VK, Christian EP, Robinson JH, Deadwyler SA, Dudek FE. Cholinergic excitation of supraoptic neurons in hypothalamic slices of rat. Neuropharmacology. 27: 721-7. PMID 3419551 DOI: 10.1016/0028-3908(88)90081-0  1
1988 Gribkoff VK, Dudek FE. The effects of the excitatory amino acid antagonist kynurenic acid on synaptic transmission to supraoptic neuroendocrine cells. Brain Research. 442: 152-6. PMID 2834012 DOI: 10.1016/0006-8993(88)91443-6  1
1988 Dudek FE, Gribkoff VK, Olson JE, Hertzberg EL. Reduction of dye coupling in glial cultures by microinjection of antibodies against the liver gap junction polypeptide. Brain Research. 439: 275-80. PMID 2833985 DOI: 10.1016/0006-8993(88)91484-9  1
1987 Dudek FE, Gribkoff VK. Synaptic activation of slow depolarization in rat supraoptic nucleus neurones in vitro. The Journal of Physiology. 387: 273-96. PMID 3656173  1
1985 Gribkoff VK, Ashe JH. Responses of opossum and rat hippocampal CA1 cells to paired stimulus volleys. Brain Research Bulletin. 15: 273-8. PMID 4052826 DOI: 10.1016/0361-9230(85)90150-9  1
1984 Gribkoff VK, Ashe JH. Modulation by dopamine of population responses and cell membrane properties of hippocampal CA1 neurons in vitro. Brain Research. 292: 327-38. PMID 6318915 DOI: 10.1016/0006-8993(84)90768-6  1
1984 Gribkoff VK, Ashe JH. Modulation by dopamine of population spikes in area CA1 hippocampal neurons elicited by paired stimulus pulses. Cellular and Molecular Neurobiology. 4: 177-83. PMID 6091884 DOI: 10.1007/BF00711003  1
1982 Lee K, Schubert P, Gribkoff V, Sherman B, Lynch G. A combined in vivo/in vitro study of the presynaptic release of adenosine derivatives in the hippocampus Journal of Neurochemistry. 38: 80-83. PMID 7108536  1
1977 Lynch GS, Dunwiddie T, Gribkoff V. Heterosynaptic depression: a postsynaptic correlate of long term potentiation Nature. 266: 737-739. PMID 195211  1
1976 Spencer HJ, Gribkoff VK, Cotman CW, Lynch GS. GDEE antagonism of iontophoretic amino acid excitations in the intact hippocampus and in the hippocampal slice preparation. Brain Research. 105: 471-81. PMID 1260458 DOI: 10.1016/0006-8993(76)90594-1  1
1976 Deadwyler SA, Gribkoff V, Cotman C, Lynch G. Long lasting changes in the spontaneous activity of hippocampal neurons following stimulation of the entorhinal cortex. Brain Research Bulletin. 1: 1-7. PMID 974790 DOI: 10.1016/0361-9230(76)90043-5  1
1976 Lynch GS, Gribkoff VK, Deadwyler SA. Long term potentiation is accompanied by a reduction in dendritic responsiveness to glutamic acid. Nature. 263: 151-3. PMID 967251 DOI: 10.1038/263151a0  1
Show low-probability matches.